Media headlines about Neurometrix (NASDAQ:NURO) have trended somewhat negative on Thursday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neurometrix earned a media sentiment score of -0.04 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 48.2410282871856 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of Neurometrix traded down $0.02, hitting $1.23, during trading on Thursday, Marketbeat.com reports. The stock had a trading volume of 100 shares, compared to its average volume of 447,662. Neurometrix has a 12-month low of $1.20 and a 12-month high of $3.18.
Neurometrix (NASDAQ:NURO) last announced its quarterly earnings data on Friday, April 20th. The medical device company reported $0.08 earnings per share (EPS) for the quarter. Neurometrix had a negative return on equity of 161.28% and a negative net margin of 47.75%. The firm had revenue of $4.94 million during the quarter.
Neurometrix Company Profile
NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.
Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.